Quell TX Logo (RGB)-100.jpg
Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors
10 juil. 2024 07h00 HE | Quell TX
Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in...
Quell TX Logo (RGB)-100.jpg
Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients
04 juin 2024 13h30 HE | Quell TX
Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...
BioNTech präsentiert
BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
21 mai 2024 06h45 HE | BioNTech SE
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31....
BioNTech to Present
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
21 mai 2024 06h45 HE | BioNTech SE
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at...
BioNTech und Autolus
BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme
08 févr. 2024 05h45 HE | BioNTech SE
Die Unternehmen nutzen in der strategischen Zusammenarbeit Produktionskapazitäten, kommerzielle Infrastruktur sowie Technologien mit dem Ziel, die autologen CAR-T-Programme beider Unternehmen...
BioNTech and Autolus
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 
08 févr. 2024 05h45 HE | BioNTech SE
Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market...
market-digits.jpg
Advanced Therapy Medicinal Products Market to Accumulate a Valuation of USD 61.5 Billion by 2030, Advancing at a 13.4% CAGR | MarketDigits Richmond, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to a research report "Advanced Therapy Medicinal Products Market”, by Therapy Type (Cell Therapy {Stem Cell Therapy, Non-stem Cell Therapy},...
BioNTech präsentiert
BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023
23 oct. 2023 11h30 HE | BioNTech SE
BNT211 hat das Potential, die erste Therapie dieser Art zu werden, indem der Kandidat zwei innovative Ansätze kombiniert: eine autologe CAR-T-Zelltherapie mit dem onkofetalen Antigen Claudin-6 (CLDN6)...
BioNTech Presents Po
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
23 oct. 2023 11h30 HE | BioNTech SE
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T...
Roots-Analysis-Logo.png
The CAR-T cell therapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis
15 févr. 2023 10h00 HE | Roots Analysis
London, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 ” report to its list of offerings. CAR-T cell...